A Foundation Building Strength
EIN: 26-1761329
Programs and results
What we aim to solve
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
NEMALINE MYOPATHY RESEARCH GRANTS
GRANTS AWARDED TO RESEARCH INVESTIGATORS TO FIND A CURE/TREATMENT FOR NEMALINE MYOPATHY.
NEMALINE MYOPATHY CONFERENCE
ENGAGEMENT CONFERENCE FOR FAMILIES WITH NEMALINE MYOPATHY, CLINICIANS AND RESEARCH INVESTIGATORS
Where we work
External reviews

Photos
Goals & Strategy
Learn about the organization's key goals, strategies, capabilities, and progress.
Charting impact
Four powerful questions that require reflection about what really matters - results.
What is the organization aiming to accomplish?
A Foundation Building Strength has a laser focused mission to find treatments for Nemaline Myopathy and to support families who have been affected by the debilitating disease.
What are the organization's key strategies for making this happen?
A Foundation Building Strength has three main strategies for getting to treatment:\r\n\r\n1. Review and analyze previous research accomplishments and develop key strategies for speed to treatment.\r\n2. Raise enough funds to be able to fund research proposals on a bi-annual basis.\r\n3. Provide education and engagement opportunities such as webinars and conferences for families of those affected by Nemaline Myopathy, clinicians and research investigators.
What are the organization's capabilities for doing this?
A Foundation has a committed Board of Directors and a strong support community. Although the Nemaline Myopathy community is very small, they are very dedicated to helping find treatments for NM.
What have they accomplished so far and what's next?
We have not yet found a treatment/cure for Nemaline Myopathy. \r\nWe have published the Care Protocol for Congenital Myopathies.\r\nWe host family conferences every year.\r\nWe host a Nemaline Myopathy Conference every other year.\r\nWe have established partnerships with other organizations to help further our quest for NM treatment.\r\nWe participate in the Congenital Myopathy Registry.\r\nWe have funded a Congenital Myopathy Tissue Registry.
Financials
Revenue vs. expenses: breakdown
Liquidity in 2021 info
14.62
Months of cash in 2021 info
30.1
Fringe rate in 2021 info
0%
Funding sources info
Assets & liabilities info
A Foundation Building Strength
Revenue & expensesFiscal Year: Jan 01 - Dec 31
SOURCE: IRS Form 990
A Foundation Building Strength
Balance sheetFiscal Year: Jan 01 - Dec 31
SOURCE: IRS Form 990
The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.
Fiscal Year: Jan 01 - Dec 31
SOURCE: IRS Form 990
This snapshot of A Foundation Building Strength’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.
Created in partnership with
Business model indicators
Profitability info | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
Unrestricted surplus (deficit) before depreciation | $180,428 | -$170,867 | $140,773 | $116,120 | $542,973 |
As % of expenses | 65.0% | -25.2% | 46.9% | 47.1% | 93.0% |
Unrestricted surplus (deficit) after depreciation | $180,428 | -$170,867 | $140,773 | $116,120 | $542,973 |
As % of expenses | 65.0% | -25.2% | 46.9% | 47.1% | 93.0% |
Revenue composition info | |||||
---|---|---|---|---|---|
Total revenue (unrestricted & restricted) | $458,196 | $506,009 | $440,714 | $362,525 | $1,126,904 |
Total revenue, % change over prior year | -23.3% | 10.4% | -12.9% | -17.7% | 210.8% |
Program services revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Membership dues | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Investment income | 0.4% | 1.1% | 1.3% | 0.1% | 0.1% |
Government grants | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
All other grants and contributions | 99.6% | 98.6% | 99.0% | 99.7% | 99.9% |
Other revenue | 0.0% | 0.3% | -0.3% | 0.1% | 0.0% |
Expense composition info | |||||
---|---|---|---|---|---|
Total expenses before depreciation | $277,757 | $676,876 | $299,941 | $246,405 | $583,931 |
Total expenses, % change over prior year | -13.0% | 143.7% | -55.7% | -17.8% | 137.0% |
Personnel | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Professional fees | 24.2% | 7.3% | 23.4% | 21.8% | 16.1% |
Occupancy | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Interest | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Pass-through | 61.7% | 90.6% | 54.8% | 74.1% | 80.9% |
All other expenses | 14.1% | 2.2% | 21.8% | 4.1% | 3.0% |
Full cost components (estimated) info | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
Total expenses (after depreciation) | $277,757 | $676,876 | $299,941 | $246,405 | $583,931 |
One month of savings | $23,146 | $56,406 | $24,995 | $20,534 | $48,661 |
Debt principal payment | $0 | $0 | $0 | $0 | $0 |
Fixed asset additions | $0 | $0 | $0 | $0 | $0 |
Total full costs (estimated) | $300,903 | $733,282 | $324,936 | $266,939 | $632,592 |
Capital structure indicators
Liquidity info | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
Months of cash | 45.0 | 20.5 | 45.2 | 50.0 | 30.1 |
Months of cash and investments | 45.0 | 20.5 | 45.2 | 50.0 | 30.1 |
Months of estimated liquid unrestricted net assets | 47.0 | 16.3 | 42.4 | 57.2 | 35.3 |
Balance sheet composition info | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
Cash | $1,042,413 | $1,154,532 | $1,129,304 | $1,026,074 | $1,464,989 |
Investments | $0 | $0 | $0 | $0 | $0 |
Receivables | $55,560 | $38,965 | $43,221 | $65,920 | $34,445 |
Gross land, buildings, equipment (LBE) | $0 | $0 | $0 | $0 | $0 |
Accumulated depreciation (as a % of LBE) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Liabilities (as a % of assets) | 1.0% | 23.2% | 9.9% | 3.7% | 5.6% |
Unrestricted net assets | $1,088,674 | $917,807 | $1,058,580 | $1,174,700 | $1,717,672 |
Temporarily restricted net assets | $0 | $0 | N/A | N/A | N/A |
Permanently restricted net assets | $0 | $0 | N/A | N/A | N/A |
Total restricted net assets | $0 | $0 | $0 | $0 | $0 |
Total net assets | $1,088,674 | $917,807 | $1,058,580 | $1,174,700 | $1,717,672 |
Key data checks
Key data checks info | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
Material data errors | No | No | No | No | No |
Operations
The people, governance practices, and partners that make the organization tick.
Documents
Executive Director
Mr. Marc Guillet
Dana and Marc Guillet, who live in Palo Alto, CA gave birth to their third child, Ava, after an uneventful full term pregnancy. With all normal pre-natal visits and amnio testing, their expectations were set for another easy delivery and a short trip home to share Ava with her siblings, Samantha and Andrew.\r\n\r\nAt birth, Ava had some obvious problems. Her hands and feet were mal-positioned and her cry was very weak. The doctors thought because she delivered quickly she would come around within several hours. Three weeks later in the neonatal intensive care unit, Marc and Dana were still learning how to care for their child that had no diagnosis.\r\n\r\nAva could not take milk on her own and on occasion would stop breathing in her sleep. Ava left the hospital with a tube passing from her nose to her stomach for feeding, monitors to tell the Guillets when she stopped breathing, and a suction machine to manage her saliva which she could not swallow. At 7 months, Ava had a feeding tube placed directly through her stomach wall and a muscle biopsy confirming a diagnosis of Nemaline Myopathy.\r\n\r\nAva is currently walking, though she falls more than typical children. She still requires on-going occupational, physical and swallowing therapy on a regular basis. She is 9 and is going into the fourth grade. \r\n\r\nAva is beautiful, happy, bright and certainly tolerant after all of the different doctors and procedures that she has endured.
Treasurer
Kelly Lloyd
Willie Quinn is a life sciences entrepreneur with a passion for making a difference. Willie is CEO and co-founder of Bullet Biotechnology, a company developing a therapeutic vaccine for B-cell lymphomas based on technology invented at Stanford University. Prior to Bullet Biotech, Willie ran Corporate Development for Jazz Pharmaceuticals, a public specialty pharmaceutical company with experience developing and commercializing drugs for orphan indications (indications with fewer than 200,000 patients in the U.S.). Willie joined Jazz Pharmaceuticals in 2003 and actively participated in the creation of their first business plan, working in various functions such as business development, strategy, and finance over his 8 years at the company. Prior to Jazz Pharmaceuticals, Willie was COO and CFO at Novation Biosciences, a venture-backed startup developing software to extract meaningful information from microarray data.\r\n\r\nWillie has an MBA from the Stanford Graduate School of Business and an MA and a BA from Stanford University.
Number of employees
Source: IRS Form 990
A Foundation Building Strength
Officers, directors, trustees, and key employeesSOURCE: IRS Form 990
Compensation data
There are no highest paid employees recorded for this organization.
A Foundation Building Strength
Board of directorsas of 02/02/2023
Board of directors data
Marc Guillet
Agile Physical Therapy
Term: 2008 - 2016
Boris Shimanovsky
Factual
Board leadership practices
GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.
-
Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? No -
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? No -
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? No -
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? No -
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? No